RecruitingPhase 1NCT07335198
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
Studying NON RARE IN EUROPE: Non-alcoholic fatty liver disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GlaxoSmithKline
- Principal Investigator
- GSK Clinical TrialsGlaxoSmithKline
- Intervention
- Efimosfermin alfa(drug)
- Enrollment
- 30 target
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2026 – 2026
Study locations (1)
- GSK Investigational Site, Auckland, New Zealand
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07335198 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07366710Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PETRigshospitalet, Denmark
- RECRUITINGPHASE4NCT06449833Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLDZhujiang Hospital
- RECRUITINGNANCT06413069Effects of Almonds in Glucose-intolerant Adults (AGAMEMNON)Charite University, Berlin, Germany
- RECRUITINGNANCT06275906Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters.Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
- RECRUITINGPHASE1NCT05979389Bicalutamide Therapy in Young Women With NAFLD and PCOSUniversity of California, San Francisco
- RECRUITINGNANCT06704321Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLDValbiotis
- ACTIVE NOT RECRUITINGNANCT06697977Effects of Phytosterol Supplementation on Liver Function and Inflammatory Status in Patients with Nonalcoholic Fatty Liver DiseaseUniversity of Jordan
- RECRUITINGPHASE4NCT05644717Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLDGetz Pharma
See all trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease →